For instance, mutations in the adenomatous polyposis coli (APC) gene or β-catenin are frequently observed in CRC, resulting in persistent activation of the Wnt/β-catenin pathway.22,23 Similarly, aberrant Wnt signaling has been implicated in liver, breast, gastric, and several other cancers.12,24–27 Given its critical involvement in cancer, targeting various elements of the Wnt pathway—such as Frizzled (Fzd) receptors, β-catenin, and downstream effectors—offers promising avenues for the development of novel anticancer therapies. This evidence concerns the gene APC and colorectal carcinoma.